RxDoctor Payments Data

Jyoti Supanekar, MD

Psychiatry · Woodbridge, VANPI 1902943483

Payments from drug & device makers

$475in general payments, 2019–2025

Across 13 payments — averaging $36.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$100
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$100
  • Johnson & Johnson$85
  • Teva Pharmaceuticals USA, Inc.$54
  • E.r. Squibb & Sons, L.L.C.$53
  • Alkermes, Inc.$39
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$41086%
  • Education$6414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475 in reported general payments places this provider in the 60th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$10,633
Medicare patients
13
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$86,301
AristadaAripiprazole Lauroxil12$38,284
Abilify MaintenaAripiprazole14$32,079
VyvanseLisdexamfetamine Dimesylate11$4,291
Aripiprazole62$4,117
Clozapine46$2,097
Olanzapine OdtOlanzapine28$1,838
Fluvoxamine Maleate17$1,255
Risperidone66$714
Divalproex Sodium ErDivalproex Sodium27$628
Olanzapine31$574
Venlafaxine Hcl ErVenlafaxine Hcl23$570
Benztropine Mesylate48$523
Haloperidol14$421
Divalproex Sodium25$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$85$86,30127 claims
Alkermes, Inc.Aristada$39$38,28412 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$100$32,07914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →